

Supporting Information

Synthesis, Structures, and Conformational Characteristics of Pillararene-based Diels-Alder Adducts with Embedded Chiral Centres

Haiying Wang,^a Tushar Ulhas Thikekar,^{a,b} Jingfeng Xue,^b Yumei Zhu,^a Wangjian Fang,^a Jiong Xu,^a Andrew C.-H. Sue,^{b,*} and Hongxia Zhao^{a,*}

a. School of Pharmaceutical Science & Technology, Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, P. R. China.

China.

b. College of Chemistry and Chemical Engineering, Xiamen University, 422 Siming S Rd, Siming District, Xiamen, Fujian Province 361005, P. R. China.

* Corresponding E-mail address: andrewsue@xmu.edu.cn; zhaohongxia@tju.edu.cn.

Table of Contents


| | |
|---------------------------------------|-----|
| 1. Materials and General Methods..... | S2 |
| 2. Synthetic Procedures..... | S3 |
| 3. Conformational Change Studies..... | S28 |
| 4. X-Ray Crystallography..... | S29 |
| 5. Resolution of DA adducts..... | S42 |
| 6. References..... | S46 |

1. Materials and General Methods

Starting materials, reagents, and solvents were purchased from commercial vendors and used as received, unless otherwise noted. All reactions were performed under an Ar atmosphere and in dry solvents, unless otherwise stated. Analytical thin-layer chromatography (TLC) was performed on aluminum sheets, precoated with silica gel GF254. Flash column chromatography was performed over silica gel (200–300 mesh or 300–400 mesh). ^1H , ^{13}C and 2D NMR spectra were recorded on Bruker Avance 400 MHz and 600 MHz spectrometers at 298 K, unless otherwise noted. The chemical shifts are listed in ppm on the δ scale and coupling constants were recorded in Hertz (Hz). Chemical shifts are calibrated relative to the signals corresponding of the non-deuterated solvents (CHCl_3 : δ 7.26 ppm for ^1H and 77.16 ppm for ^{13}C). The following abbreviations were used for multiplicities: s, singlet; d, doublet; t, triplet; m, multiplet or overlapping peaks; b, broad peaks. High-resolution mass spectra (HRMS) were measured on a Q-ExactiveTM HF/UltiMateTM 3000 RSLCnano using a Nano ProFlow meter with ProFlow technology in positive mode. High-performance liquid chromatography (HPLC) analyses were operated using a LC-16A instrument (shimadzu corporation kyoto Japan). The separation was performed on a CHIRALPAK IE HPLC analytical column (5 μm , ID 4.6 mm \times L 250 mm) purchased from Daicel Chemical Industries. The ECD spectra were recorded in the range 600 to 220 nm, a step size of 1.0 nm, a bandwidth of 2 nm on JASCO J-810 circular dichroism spectrometer at ambient conditions.

Single crystals suitable for X-ray diffraction were selected and mounted in inert oil in cold gas stream and their X-ray diffraction intensity data was collected on a Rigaku XtaLAB FRX diffractometer equipped with the Hypix6000HE detector, using Cu $K\alpha$ radiation ($\lambda = 1.54184 \text{ \AA}$) and a Rigaku XtaLAB Synergy diffractometer equipped with the Hypix6000HE detector, using Mo $K\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$). By the use of Olex2,¹ the structure was solved either (i) with the ShelXT structure solution program using Direct Methods or (ii) with the ShelXM structure solution program using Dual Space and (iii) refined with the ShelXL refinement package using Least Squares minimisation.² All non-hydrogen atoms were refined with anisotropic thermal parameters except the disordered carbon atoms. The hydrogen atoms were set in calculated positions and refined as riding atoms with a common fixed isotropic thermal parameter. Selected details of the data collection and structural refinement of each compound can be found within Table S1–S5 and full details are available in the corresponding CIF files. Crystallographic data (excluding structure factors) have been deposited with the Cambridge Crystallographic Data Centre and may be obtained free of charge via http://www.ccdc.cam.ac.uk/data_request/cif.

2. Synthetic Procedures



Scheme S1. Synthesis of **MeP[5]DA-1**.

MeP[5]: To a solution of 1,4-dimethoxybenzene (1.38 g, 10 mmol) and $(\text{CH}_2\text{O})_n$ (0.30 g, 10 mmol) in 1,2-dichloroethane (100 mL), trifluoroacetic acid (5 mL) was added. The reaction mixture was refluxed for 2 h. After cooling, the reaction mixture was poured into methanol. The resulting precipitate of **MeP[5]** was collected by filtration. The crude product (1.20 g, 80%) was directly used in the following procedure without further purification.

MeP[5]Q: To a solution of **MeP[5]** (1.5 g, 2 mmol) in CH_2Cl_2 (200 mL) was added the solution of $(\text{NH}_4)_2\text{Ce}(\text{NO}_3)_6$ (2.2 g, 4 mmol) in water (2 mL) by dropwise, resulting in a red-coloured mixture which was stirred at $25\text{ }^\circ\text{C}$ for 10 min. Water (100 mL) was added and the mixture was washed with copious amounts of water, the organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The residue was subjected to chromatography (EtOAc/*n*-hexane, 10/90) to afford the red solid product (840 mg, 60%). Data in accordance to literature.³

MeP[5]DA-1: **MeP[5]Q** (200 mg, 0.28 mmol) and 1,3-butadiene (1.9 mol/L in hexane, 10 mL, 19 mmol) was added into a dried Schlenk vessel with teflon-protected vacuum valve. The mixture was heated at $130\text{ }^\circ\text{C}$ for 48 h. Upon cooling to room temperature, the reaction mixture was concentrated and purified by silica column chromatography (EtOAc/*n*-hexane, 2/5) and afford the product as yellow solid (88.9 mg, 41%). ^1H NMR (600 MHz, CDCl_3) δ 7.03 (s, 1H), 6.98 (s, 1H), 6.77 (s, 1H), 6.66 (s, 1H), 6.65 (s, 1H), 6.57 (s, 1H), 6.44 (s, 1H), 6.14 (d, $J = 1.9\text{ Hz}$, 1H), 5.66–5.58 (m, 2H), 5.07 (s, 1H), 3.96–3.89 (m, 4H), 3.88 (s, 1H), 3.81 (d, $J = 13.6\text{ Hz}$, 1H), 3.77 (m, 12H), 3.74 (s, 3H), 3.65 (d, $J = 16.0\text{ Hz}$, 1H), 3.61 (s, 3H), 3.48 (s, 3H), 3.24 (d, $J = 15.7\text{ Hz}$, 1H), 2.97 (d, $J = 13.4\text{ Hz}$, 1H), 2.91 (t, $J = 7.5\text{ Hz}$, 1H), 2.70 (d, $J = 13.4\text{ Hz}$, 1H), 2.40 (d, $J = 18.0\text{ Hz}$, 1H), 2.25–2.20 (m, 2H), 1.84 (d, $J = 18.0\text{ Hz}$, 1H), 1.76 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 201.2, 199.9, 152.0, 151.2, 151.1, 151.1, 151.0, 150.5, 150.4, 147.3, 136.8, 130.3, 129.8, 129.6, 127.5, 126.5, 125.5, 124.5, 124.0, 121.3, 114.8, 114.1, 114.1, 114.1, 113.8, 113.6, 113.3, 111.1, 56.3, 56.2, 56.1, 56.0, 56.0, 55.9, 55.4, 52.7, 52.3, 51.9, 40.9, 30.8, 29.7, 29.4, 28.3, 26.4. HRMS (ESI) m/z $[\text{M} + \text{NH}_4]^+$ Calcd for $\text{C}_{47}\text{H}_{54}\text{O}_{10}\text{N}$ 792.3742, found 792.3732.




Fig. S1. ^1H NMR (600 MHz) spectrum of **MeP[5]DA-1** recorded in CDCl_3 at 298 K.




Fig. S2. ^{13}C NMR (150 MHz) spectrum of **MeP[5]DA-1** recorded in CDCl_3 at 298 K.




Fig. S3. DEPT 135° spectrum of **MeP[5]DA-1** recorded in CDCl_3 at 298 K.




Fig. S4. ^1H - ^1H COSY NMR spectrum of **MeP[5]DA-1** recorded in CDCl_3 at 298 K.




Fig. S5. ^1H - ^{13}C HSQC NMR spectra of **MeP[5]DA-1** recorded in CDCl_3 at 298 K.




Fig. S6. ^1H - ^{13}C HMBC NMR spectrum of **MeP[5]DA-1** recorded in CDCl_3 at 298 K.




Fig. S7. ^1H - ^1H ROESY NMR spectrum of **MeP[5]DA-1** recorded in CDCl_3 at 298 K.

MeP[5]DA-1: ^1H NMR (400 MHz, CD_3CN) δ 7.03 (s, 1H), 7.00 (s, 1H), 6.84 (s, 1H), 6.78 (s, 1H), 6.74 (s, 1H), 6.72 (s, 1H), 6.54 (s, 1H), 6.29 (s, 1H), 5.91 (s, 1H), 5.69–5.66 (m, 1H), 5.58–5.53 (m, 1H), 3.84–3.76 (m, 9H), 3.67 (s, 3H), 3.62 (s, 3H), 3.52 (s, 3H), 3.31 (d, $J = 14.1$ Hz, 1H), 2.96 (s, 2H), 2.63 (m, 4H), 2.34–2.25 (m, 1H), 2.24–2.08 (m, 3H), 1.91–1.82 (m, 1H). ^{13}C NMR (101 MHz, CD_3CN) δ 201.5, 200.5, 152.0, 151.7, 151.6, 151.2, 151.2, 151.1, 151.0, 149.5, 136.0, 130.1, 130.1, 129.7, 129.7, 128.5, 127.3, 125.5, 124.9, 123.9, 123.6, 117.9, 115.2, 115.0, 114.4, 114.1, 113.9, 113.8, 113.6, 113.2, 56.3, 56.1, 56.1, 56.0, 55.9, 55.9, 55.7, 54.43, 52.6, 50.3, 36.5, 32.6, 30.4, 29.5, 29.1, 29.0, 23.8.




Fig. S8. (a) ^1H NMR (400 MHz) and (b) ^{13}C NMR (101 MHz) spectra of **MeP[5]DA-1** recorded in CD_3CN at 298 K.




Fig. S9. ^1H - ^1H COSY NMR spectrum of **MeP[5]DA-1** recorded in CD_3CN at 298 K.




Fig. S10. ^1H - ^{13}C HSQC NMR spectrum of **MeP[5]DA-1** recorded in CD_3CN at 298 K.




Fig. S11. ^1H - ^{13}C HMBC NMR spectrum of **MeP[5]DA-1** recorded in CD_3CN at 298 K.





Fig. S12. ^1H - ^1H ROESY NMR spectrum of **MeP[5]DA-1** recorded in CD_3CN at 298 K.

MeP[5]DA-1: ^1H NMR (400 MHz, d_6 -DMSO) δ 7.01 (s, 1H), 6.96 (s, 1H), 6.85 (s, 1H), 6.80 (s, 1H), 6.71 (s, 1H), 6.60 (s, 2H), 5.96 (d, $J = 2.0$ Hz, 1H), 5.56–5.53 (m, 2H), 4.95 (s, 1H), 3.87–3.78 (m, 4H), 3.77–3.66 (m, 12H), 3.55 (s, 3H), 3.37 (s, 3H), 3.19 (d, $J = 15.6$ Hz, 1H), 2.84 (t, $J = 7.6$ Hz, 1H), 2.81–2.72 (m, 2H), 2.19–2.06 (m, 3H), 1.89 (d, $J = 18.0$ Hz, 1H), 1.67 (s, 3H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 200.6, 199.2, 151.8, 151.0, 151.0, 150.9, 150.8, 150.5, 150.3, 147.4, 136.3, 130.0, 129.5, 129.4, 129.0, 127.4, 126.2, 125.9, 125.0, 124.2, 121.7, 115.3, 114.9, 114.2, 114.2, 113.8, 113.5, 113.4, 110.6, 56.5, 56.5, 56.4, 56.3, 56.2, 56.1, 55.6, 52.6, 52.0, 51.5, 30.3, 29.6, 29.4, 27.8, 26.4.

(a)



(b)




Fig. S13. (a) ^1H NMR (400 MHz) and (b) ^{13}C NMR (101 MHz) spectra of **MeP[5]DA-1** recorded in d_6 -DMSO at 298 K.




Fig. S14. ^1H - ^1H COSY NMR spectrum of **MeP[5]DA-1** recorded in d_6 -DMSO at 298 K.




Fig. S15. ^1H - ^{13}C HMBC NMR spectrum of **MeP[5]DA-1** recorded in d_6 -DMSO at 298 K.




Fig. S16. ^1H - ^{13}C HSQC NMR spectrum of **MeP[5]DA-1** recorded in d_6 -DMSO at 298 K.




Fig. S17. ^1H - ^1H ROESY NMR spectrum of **MeP[5]DA-1** recorded in d_6 -DMSO at 298 K.




Fig. S18. Full ESI-MS spectrum of MeP[5]DA-1 in positive mode.






Fig. S19. Experimental (top) and stimulated (bottom) ESI-MS spectra of MeP[5]DA-1.



Scheme S2. Synthesis of **MeP[5]DA-2**.

MeP[5]DA-2: **MeP[5]Q** (400 mg, 0.56 mmol) and 2,4-hexadiene (mixture of isomer, 4 mL, 34 mmol) was added into a dried Schlenk vessel with teflon-protected vacuum valve. The mixture was heated at 130 °C and stirred for 24 h. Upon cooling to room temperature, the reaction mixture was concentrated under reduced pressure and purified by silica column chromatography (EtOAc/*n*-hexane, 1/3) and afford the product as yellow solid (98.4 mg, 22%). ¹H NMR (400 MHz, CDCl₃) δ 6.97 (s, 2H), 6.67 (s, 1H), 6.61 (s, 1H), 6.58 (s, 1H), 6.50 (s, 1H), 6.18 (d, *J* = 1.6 Hz, 1H), 5.61 (m, 2H), 5.52 (m, 1H), 4.02–3.91 (m, 3H), 3.86–3.58 (m, 26H), 3.05 (dd, *J* = 14.6, 1.9 Hz, 1H), 2.94 (s, 3H), 2.77 (d, *J* = 5.2 Hz, 1H), 2.58 (s, 3H), 2.52 (d, *J* = 15.2 Hz, 1H), 2.36 (m, 1H), 2.14 (m, 1H), 1.09 (d, *J* = 7.5 Hz, 1H), 0.79 (d, *J* = 7.3, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 202.6, 202.1, 155.6, 151.7, 151.6, 151.1, 151.0, 150.8, 150.6, 150.2, 135.1, 130.0, 129.8, 129.5, 129.4, 128.5, 126.9, 125.9, 125.4, 123.0, 114.6, 114.3, 114.2, 114.1, 114.1, 113.4, 111.2, 111.0, 56.2, 56.1, 56.1, 56.0, 56.0, 54.8, 54.1, 53.4, 49.8, 40.2, 39.8, 30.3, 30.1, 29.9, 29.0, 27.8, 19.0, 17.7. HRMS (ESI) *m/z* [M + NH₄]⁺ Calcd for C₄₇H₅₄O₁₀N 820.4055, found 820.4067

(a)



(b)




Fig. S20. (a) ¹H NMR (400 MHz) and (b) ¹³C NMR (101 MHz) spectra of **MeP[5]DA-2** recorded in CDCl₃ at 298 K.




Fig. S21. ^1H - ^1H COSY NMR spectra of **MeP[5]DA-2** recorded in CDCl_3 at 298 K.




Fig. S22. ^1H - ^{13}C HMBC NMR spectra of **MeP[5]DA-2** recorded in CDCl_3 at 298 K.




Fig. S23. ^1H - ^1H NOESY NMR spectra of **MeP[5]DA-2** recorded in CDCl_3 at 298 K.




Fig. S24. ^1H - ^{13}C HSQC NMR spectra of **MeP[5]DA-2** recorded in CDCl_3 at 298 K.




Fig. S25. Full ESI-MS spectrum of **MeP[5]DA-2** in positive mode.





Fig. S26. Experimental (top) and stimulated (bottom) ESI-MS spectra of **MeP[5]DA-2**.



Scheme S3. Synthesis of **EtP[5]DA**.

EtP[5]: To a solution of 1,4-diethoxybenzene (1.66 g, 10 mmol) and $(\text{CH}_2\text{O})_n$ (0.90 g, 30 mmol) in CH_2Cl_2 (150 mL), FeCl_3 (243 mg, 1.5 mmol) was added. The reaction mixture at 25 °C for 2 h. Water (200 mL) was poured into the reaction mixture. The organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by silica column chromatography ($\text{CH}_2\text{Cl}_2/n$ -hexane, 1/2) and afford the product as white solid (1.09 g, 61%). Data in accordance to literature.⁴

EtP[5]Q: To a solution of **EtP[5]** (890 mg, 1 mmol) in CH_2Cl_2 (100 mL) was added the solution of $(\text{NH}_4)_2\text{Ce}(\text{NO}_3)_6$ (1.1 g, 2 mmol) in water (5 mL) by dropwise, resulting in a red-coloured mixture which was stirred at 25 °C for 10 min. Water (100 mL) was added and the mixture was washed with copious amounts of water, the organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The residue was subjected to chromatography (EtOAc/n -hexane, 10/90) to afford the red solid product (340 mg, 41%). Data in accordance to literature.⁵

EtP[5]DA: **EtP[5]Q** (340 mg, 0.41 mmol) and 1,3-butadiene (1.9 mol/L in hexane, 10 mL, 19 mmol) was added into a dried Schlenk vessel with teflon-protected vacuum valve. The mixture was heated at 130 °C and stirred for 48 h. Upon cooling to room temperature, the reaction mixture was concentrated under reduced pressure and purified by silica column chromatography (EtOAc/n -hexane, 2/5) and afford the product as yellow solid (165 mg, 45%). ^1H NMR (400 MHz, CDCl_3) δ 6.98 (s, 1H), 6.92 (s, 1H), 6.76 (s, 1H), 6.64 (s, 1H), 6.60 (s, 2H), 6.48 (s, 1H), 6.45 (s, 1H), 5.89 (s, 1H), 5.72 (d, $J = 10.0$ Hz, 1H), 5.57 (d, $J = 9.8$ Hz, 1H), 4.03–3.59 (m, 20H), 3.34 (d, $J = 14.7$ Hz, 1H), 3.17 (d, $J = 14.2$ Hz, 1H), 2.99 (d, $J = 6.9$ Hz, 2H), 2.89 (d, $J = 14.2$ Hz, 1H), 2.79 (d, $J = 6.2, 4.1$ Hz, 1H), 2.39 (d, $J = 18.2$ Hz, 1H), 2.32–2.23 (m, 1H), 2.16–2.05 (m, 1H), 1.87 (d, $J = 18.9$ Hz, 1H), 1.49–1.34 (m, 12H), 1.31–1.21 (m, 6H), 1.10 (t, $J = 6.9$ Hz, 3H), 0.48 (t, $J = 6.9$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 200.8, 199.9, 149.6, 149.4, 149.2, 148.9, 148.9, 148.8, 148.8, 148.6, 147.9, 135.0, 128.9, 128.8, 128.5, 128.4, 127.0, 126.1, 124.2, 122.6, 122.2, 122.1, 114.9, 114.5, 114.3, 114.0, 113.9, 113.7, 113.2, 112.7, 63.5, 63.3, 63.2, 63.0, 62.9, 62.8, 62.3, 61.4, 50.9, 48.1, 32.2, 29.1, 28.8, 28.1, 21.7, 14.3, 14.3, 14.2, 14.2, 14.0, 13.9, 13.7, 12.4. HRMS (ESI) m/z $[\text{M} + \text{NH}_4]^+$ Calcd for $\text{C}_{47}\text{H}_{54}\text{O}_{10}\text{N}$ 904.4994, found 904.5010.




Fig. S27. ^1H NMR (400 MHz) spectrum of EtP[5]DA recorded in CDCl_3 at 298 K.




Fig. S28. ^{13}C NMR (400 MHz) spectrum of EtP[5]DA recorded in CDCl_3 at 298 K.




Fig. S29. ^1H - ^1H COSY NMR spectra of **EtP[5]DA** recorded in CDCl_3 at 298 K.




Fig. S30. ^1H - ^{13}C HMBC NMR spectra of **EtP[5]DA** recorded in CDCl_3 at 298 K.




Fig. S31. ^1H - ^1H ROESY NMR spectra of **EtP[5]DA** recorded in CDCl_3 at 298 K.




Fig. S32. ^1H - ^{13}C HSQC NMR spectra of **EtP[5]DA** recorded in CDCl_3 at 298 K.




Fig. S33. Full ESI-MS spectrum of **EtP[5]DA** in positive mode.





Fig. S34. Experimental (top) and stimulated (bottom) ESI-MS spectra of **EtP[5]DA**.



Scheme S4. Synthesis of **EtP[6]DA**.

EtP[6]: The mixture of choline chloride (2.5 g, 18 mmol) and FeCl_3 (5.8 g, 36 mmol) was heated until dark solution formed. To a solution of 1,4-diethoxybenzene (19.9 g, 120 mmol) and $(\text{CH}_2\text{O})_n$ (10.8 g, 360 mmol) in CH_2Cl_2 (1800 mL) was added the solution. The reaction mixture was stirred at 25 °C for 48 h and quenched by addition of water. The organic phase was washed with saturated aqueous NaHCO_3 . The crude product was purified by silica column chromatography (EtOAc/n -hexane, 1/15) and afford the product as white solid (7.98 g, 37%). Data in accordance to literature.⁶

EtP[6]Q: A solution of $(\text{NH}_4)_2\text{Ce}(\text{NO}_3)_6$ (0.56 g, 1.03 mmol, dissolved in 10 mL water) was added dropwise into the solution of **EtP[6]** (500 mg, 0.47 mmol) in 50 mL of $\text{CH}_2\text{Cl}_2/\text{THF}$ (1:1) and the reaction mixture was stirred at room temperature for 20 h. The mixture was washed with copious amounts of water, the organic phase was dried and concentrated. The residue was subjected to chromatography (EtOAc/n -hexane, 10/90) to obtain **EtP[6]Q** (0.24 g, 50%). Data in accordance to literature.⁷

EtP[6]DA: **EtP[6]Q** (101 mg, 0.1 mmol) and 1,3-butadiene (1.9 mol/L in hexane, 3.5 mL, 6.7 mmol) was added into a dried Schlenk vessel with teflon-protected vacuum valve. The mixture was heated at 130 °C and stirred for 48 h. Upon cooling to room temperature, the reaction mixture was concentrated under reduced pressure and purified by silica column chromatography (EtOAc/n -hexane, 2/5) and afford the product as yellow solid (26.6 mg, 25%). ^1H NMR (400 MHz, CDCl_3) δ 6.88 (s, 1H), 6.82 (s, 1H), 6.78 (s, 1H), 6.74 (s, 1H), 6.69 (s, 1H), 6.65 (s, 1H), 6.57 (s, 1H), 6.53 (s, 1H), 6.06 (s, 1H), 5.78–5.79 (m, 1H), 5.57–5.61 (m, 2H), 3.66–3.97 (m, 24H), 3.30–3.34 (dd, $J = 17.2, 2.0$ Hz, 1H), 3.20–3.28 (m, 2H), 3.14 (d, $J = 13.2$ Hz, 1H), 2.96 (t, $J = 6.4$ Hz, 1H), 2.73 (d, $J = 13.2$ Hz, 1H), 1.10–1.37 (m, 27H), 0.529 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 202.1, 200.6, 150.8, 150.8, 150.7, 150.7, 150.5, 150.5, 150.5, 150.0, 147.8, 135.5, 130.4, 130.1, 129.7, 129.0, 125.51, 128.6, 128.5, 128.2, 127.4, 124.9, 123.9, 123.0, 122.4, 116.3, 116.2, 115.5, 115.3, 115.2, 115.1, 114.9, 113.9, 64.8, 64.6, 64.4, 64.3, 64.3, 64.2, 64.1, 64.0, 63.9, 63.8, 60.5, 53.2, 52.8, 40.2, 32.9, 30.8, 30.7, 30.6, 30.5, 30.2, 29.8, 26.5, 21.2, 15.4, 15.3, 15.3, 15.3, 15.2, 15.1, 15.1, 14.3, 14.2. HRMS (ESI) m/z $[\text{M} + \text{NH}_4]^+$ Calcd for $\text{C}_{66}\text{H}_{84}\text{O}_{12}\text{N}$ 1082.5988, found 1082.5981.




Fig. S35. ^1H NMR (400 MHz) spectrum of **EtP[6]DA** recorded in CDCl_3 at 298 K.




Fig. S36. ^{13}C NMR (100 MHz) spectrum of **EtP[6]DA** recorded in CDCl_3 at 298 K.




Fig. S37. ^1H - ^1H COSY NMR spectrum (400 MHz) of **EtP[6]DA** recorded in CDCl_3 at 298 K.




Fig. S38. ^1H - ^1H ROESY NMR spectrum (400 MHz) of **EtP[6]DA** recorded in CDCl_3 at 298 K.




Fig. S39. ^1H - ^{13}C HMBC NMR spectrum of **EtP[6]DA** recorded in CDCl_3 at 298 K.




Fig. S40. ^1H - ^{13}C HSQC NMR spectrum of **EtP[6]DA** recorded in CDCl_3 at 298 K.




Fig. S41. Full ESI-MS spectrum of EtP[6]DA in positive mode.




Fig. S42. Experimental (top) and stimulated (bottom) ESI-MS spectra of EtP[6]DA.

3. Conformational Change Studies

MeP[5]DA-1 in CDCl₃




Fig. S43. ¹H NMR spectra of MeP[5]DA-1 recorded in CDCl₃ and CD₃CN at 298 K.

EtP[5]DA in CDCl₃




Fig. S44. ¹H NMR spectra of EtP[5]DA recorded in CDCl₃ and CD₃CN at 298 K.

EtP[6]DA in CDCl₃




Fig. S45. Overlaid ¹H NMR spectra of EtP[6]DA recorded in CDCl₃ (top) and CD₃CN (bottom) at 298 K.

4. X-Ray Crystallography




Fig. S46. Partial crystal Structures of **MeP[5]DA-1**. (a) 1,4-dione ring A (red), (b) Ring C (grey), (c) Ring D (grey) and (d) Ring E (grey) form a dihedral angle of $34.89^\circ/81.32^\circ/83.56^\circ/81.60^\circ$ with the bridge methylene plane (brown). The yellow atoms are methylene.




Fig. S47. Partial crystal Structures of $[\text{MeCN}\equiv\text{MeP}[5]\text{DA-1}]$. (a) 1,4-dione ring A (red), (b) Ring B (green), (c) Ring C (grey), (d) Ring D (grey) and (e) Ring E (grey) form a dihedral angle of $64.97^\circ/38.14^\circ/73.47^\circ/80.31^\circ/78.88^\circ$ with the bridge methylene plane (brown). The yellow atoms are methylene.




Fig. S48. Partial crystal Structures of **MeP[5]DA-2**. 1,4-dione ring A (red) form a dihedral angle of 83.36° with the bridge methylene plane (brown). The yellow atoms are methylene.




Fig. S49. Partial crystal Structures of **MeP[5]DA-2**. ring B (green)/ring E (blue) form a dihedral angle of $27.12^\circ/33.36^\circ$ with the bridge methylene plane (brown). The yellow atoms are methylene.

Table S1. Crystal data and structure refinement of **MeP[5]DA-1**.

| | |
|--|--|
| Empirical formula | C ₄₇ H ₅₀ O ₁₀ |
| Formula weight | 774.87 |
| Temperature / K | 159.99(10) |
| Crystal system | monoclinic |
| Space group | <i>P</i> 2 ₁ / <i>n</i> |
| <i>a</i> / Å | 21.9521(5) |
| <i>b</i> / Å | 8.76930(10) |
| <i>c</i> / Å | 23.5464(6) |
| <i>α</i> / ° | 90 |
| <i>β</i> / ° | 111.735(3) |
| <i>γ</i> / ° | 90 |
| Volume / Å ³ | 4210.54(17) |
| <i>Z</i> | 4 |
| ρ_{calc} / g cm ⁻³ | 1.222 |
| μ / mm ⁻¹ | 0.085 |
| <i>F</i> / 000 | 1648.0 |
| 2 θ range for data collection / ° | 3.994–58.37 |
| Crystal size / mm ³ | 0.2 × 0.1 × 0.1 |
| Index ranges | -29 ≤ <i>h</i> ≤ 28, -10 ≤ <i>k</i> ≤ 11, -32 ≤ <i>l</i> ≤ 30 |
| Reflections collected | 51020 |
| Independent reflections | 9681 [<i>R</i> _{int} = 0.0270, <i>R</i> _{sigma} = 0.0249] |
| Data / restraints / parameters | 9681/0/522 |
| Goodness-of-fit on <i>F</i> ² | 1.070 |
| Final <i>R</i> indices [<i>I</i> ≥ 2 σ (<i>I</i>)] | <i>R</i> ₁ = 0.0427, <i>wR</i> ₂ = 0.1140 |
| Final <i>R</i> indices [all data] | <i>R</i> ₁ = 0.0589, <i>wR</i> ₂ = 0.1218 |
| Largest diff. peak / hole / e Å ⁻³ | 0.84/-0.22 |
| CCDC | 2223646 |




Fig. S50. Perspective ORTEP drawing of X-ray structure of **MeP[5]DA-1** (displacement ellipsoids are drawn at the 50% probability level).

Table S2. Crystal data and structure refinement of [MeCN \subset MeP[5]DA-1].

| | |
|---|--|
| Empirical formula | C ₅₄ H ₆₂ O ₁₀ N ₂ |
| Formula weight / g mol ⁻¹ | 899.05 |
| Temperature / K | 160.00(10) |
| Crystal system | triclinic |
| Space group | <i>P</i> -1 |
| <i>a</i> / Å | 11.5712(2) |
| <i>b</i> / Å | 13.5551(3) |
| <i>c</i> / Å | 17.3345(4) |
| α / ° | 107.357(2) |
| β / ° | 98.929(2) |
| γ / ° | 105.723(2) |
| Volume / Å ³ | 2414.13(9) |
| <i>Z</i> | 2 |
| ρ_{calc} / g cm ⁻³ | 1.237 |
| μ / mm ⁻¹ | 0.686 |
| <i>F</i> / 000 | 960.0 |
| 2 θ range for data collection / ° | 5.526–149.276 |
| Crystal size / mm ³ | 0.2 × 0.2 × 0.2 |
| Index ranges | -14 ≤ <i>h</i> ≤ 14, -12 ≤ <i>k</i> ≤ 16, -21 ≤ <i>l</i> ≤ 20 |
| Reflections collected | 28694 |
| Independent reflections | 9536 [<i>R</i> _{int} = 0.0403, <i>R</i> _{sigma} = 0.0426] |
| Data / restraints / parameters | 9536/0/605 |
| Goodness-of-fit on <i>F</i> ² | 1.074 |
| Final <i>R</i> indices [<i>I</i> ≥ 2σ(<i>I</i>)] | <i>R</i> ₁ = 0.0419, <i>wR</i> ₂ = 0.1080 |
| Final <i>R</i> indices [all data] | <i>R</i> ₁ = 0.0536, <i>wR</i> ₂ = 0.1179 |
| Largest diff. peak / hole / e Å ⁻³ | 0.61/-0.24 |
| CCDC | 2223641 |




Fig. S51. Perspective ORTEP drawing of X-ray structure of $[\text{MeCN} \subset \text{MeP}[5]\text{DA-1}]$ (displacement ellipsoids are drawn at the 50% probability level).

Table S3. Crystal data and structure refinement of [MeCN \subset EtP[5]DA].

| | |
|---|---|
| Empirical formula | C ₅₇ H ₆₉ O ₁₀ N |
| Formula weight / g mol ⁻¹ | 928.13 |
| Temperature / K | 160.01(10) |
| Crystal system | triclinic |
| Space group | <i>P</i> -1 |
| <i>a</i> / Å | 12.0623(3) |
| <i>b</i> / Å | 13.1664(2) |
| <i>c</i> / Å | 16.5167(3) |
| α / ° | 99.2010(10) |
| β / ° | 92.828(2) |
| γ / ° | 101.636(2) |
| Volume / Å ³ | 2527.12(9) |
| <i>Z</i> | 2 |
| ρ_{calc} / g cm ⁻³ | 1.220 |
| μ / mm ⁻¹ | 0.663 |
| <i>F</i> / 000 | 996.0 |
| 2 θ range for data collection / ° | 5.44–152.732 |
| Crystal size / mm ³ | 0.1 × 0.1 × 0.1 |
| Index ranges | -15 ≤ <i>h</i> ≤ 15, -15 ≤ <i>k</i> ≤ 16, -20 ≤ <i>l</i> ≤ 16 |
| Reflections collected | 35596 |
| Independent reflections | 10101 [<i>R</i> _{int} = 0.0261, <i>R</i> _{sigma} = 0.0238] |
| Data / restraints / parameters | 10101/0/622 |
| Goodness-of-fit on <i>F</i> ² | 1.032 |
| Final <i>R</i> indices [<i>I</i> ≥ 2σ(<i>I</i>)] | <i>R</i> ₁ = 0.0387, <i>wR</i> ₂ = 0.0989 |
| Final <i>R</i> indices [all data] | <i>R</i> ₁ = 0.0425, <i>wR</i> ₂ = 0.1012 |
| Largest diff. peak / hole / e Å ⁻³ | 0.22/-0.18 |
| CCDC | 2223642 |





Fig. S52. Perspective ORTEP drawing of X-ray structure of [MeCN⊂EtP[5]DA] (displacement ellipsoids are drawn at the 50% probability level).

Table S4. Crystal data and structure refinement of **MeP[5]DA-2**.

| | |
|---|--|
| Empirical formula | C ₅₀ H ₅₄ O ₁₀ Cl ₃ |
| Formula weight / g mol ⁻¹ | 921.28 |
| Temperature / K | 293(2) |
| Crystal system | monoclinic |
| Space group | <i>P</i> 2 ₁ / <i>n</i> |
| <i>a</i> / Å | 9.1056(2) |
| <i>b</i> / Å | 23.9033(6) |
| <i>c</i> / Å | 21.7204(6) |
| <i>α</i> / ° | 90 |
| <i>β</i> / ° | 93.438(2) |
| <i>γ</i> / ° | 90 |
| Volume / Å ³ | 4719.0(2) |
| <i>Z</i> | 4 |
| ρ_{calc} / g cm ⁻³ | 1.297 |
| μ / mm ⁻¹ | 2.228 |
| <i>F</i> / 000 | 1940.0 |
| 2 θ range for data collection / ° | 5.504–133.202 |
| Crystal size / mm ³ | 0.3 × 0.3 × 0.1 |
| Index ranges | -6 ≤ <i>h</i> ≤ 10, -27 ≤ <i>k</i> ≤ 28, -25 ≤ <i>l</i> ≤ 25 |
| Reflections collected | 36780 |
| Independent reflections | 8172 [<i>R</i> _{int} = 0.1169, <i>R</i> _{sigma} = 0.0670] |
| Data / restraints / parameters | 8172/55/645 |
| Goodness-of-fit on <i>F</i> ² | 1.231 |
| Final <i>R</i> indices [<i>I</i> ≥ 2σ(<i>I</i>)] | <i>R</i> ₁ = 0.1145, <i>wR</i> ₂ = 0.3189 |
| Final <i>R</i> indices [all data] | <i>R</i> ₁ = 0.1413, <i>wR</i> ₂ = 0.3406 |
| Largest diff. peak / hole / e Å ⁻³ | 0.61/-0.49 |
| CCDC | 2223647 |




Fig. S53. Perspective ORTEP drawing of X-ray structure of **MeP[5]DA-2** (displacement ellipsoids are drawn at the 50% probability level).

Table S5. Crystal data and structure refinement of **EtP[6]DA** crystallised in MeCN.

| | |
|---|---|
| Empirical formula | C ₆₆ H ₈₀ O ₁₂ |
| Formula weight / g mol ⁻¹ | 1065.30 |
| Temperature / K | 160.00(10) |
| Crystal system | triclinic |
| Space group | <i>P</i> -1 |
| <i>a</i> / Å | 8.0203(6) |
| <i>b</i> / Å | 26.7025(14) |
| <i>c</i> / Å | 27.979(2) |
| α / ° | 75.127(6) |
| β / ° | 85.524(7) |
| γ / ° | 89.818(5) |
| Volume / Å ³ | 5772.7(7) |
| <i>Z</i> | 4 |
| ρ_{calc} / g cm ⁻³ | 1.226 |
| μ / mm ⁻¹ | 0.668 |
| <i>F</i> / 000 | 2288.0 |
| 2 θ range for data collection / ° | 3.424–100.868 |
| Crystal size / mm ³ | 0.05 × 0.01 × 0.01 |
| Index ranges | -4 ≤ <i>h</i> ≤ 8, -26 ≤ <i>k</i> ≤ 26, -27 ≤ <i>l</i> ≤ 27 |
| Reflections collected | 37108 |
| Independent reflections | 11928 [<i>R</i> _{int} = 0.1906, <i>R</i> _{sigma} = 0.2459] |
| Data / restraints / parameters | 11928/0/1425 |
| Goodness-of-fit on <i>F</i> ² | 0.995 |
| Final <i>R</i> indices [<i>I</i> ≥ 2σ(<i>I</i>)] | <i>R</i> ₁ = 0.1145, <i>wR</i> ₂ = 0.2703 |
| Final <i>R</i> indices [all data] | <i>R</i> ₁ = 0.2714, <i>wR</i> ₂ = 0.3702 |
| Largest diff. peak / hole / e Å ⁻³ | 0.39/-0.32 |
| CCDC | 2223643 |




Fig. S54. Perspective ORTEP drawing of X-ray structure of **EtP[6]DA** (displacement ellipsoids are drawn at the 50% probability level).

5. Resolution of DA adducts

High-performance liquid chromatography (HPLC) analyses were operated using a LC-16A instrument (shimadzu corporation kyoto Japan). The separation was performed on a CHIRALPAK IE HPLC analytical column (5 μm , ID 4.6 mm \times L 250 mm) purchased from Daicel Chemical Flow rate of the mobile phase: 0.5 mL/min; wavelength of UV-detection: 300 nm; column temperature: 25 $^{\circ}\text{C}$; sample injection volume: 10 μL . The isolation of *rac*-**MeP[5]DA-1** was using a LC-16A instrument (shimadzu corporation kyoto Japan). The isomeric mixture (10 mg) was dissolved in 12 ml of 50 % chloroform and 50 % toluene, and then collected in a single injection by the manual operation with a 2 mL syringe and 1 mL sample loop. The separation was performed on semi-preparative column (5 μm , ID 10 mm \times L 250 mm). The flow rate was 2 mL/min. The mixture was carried out using mobile phase consisting of 50 % solvent A (Chloroform) and 50 % solvent B (Toluene).




Fig. S55. Analytical HPLC chromatograms (gradient of Chloroform/Toluene, 50:50, $\lambda = 300$ nm) of samples of the resolved enantiomers (*P*, 4*aS*, 8*aR*)-**MeP[5]DA-1** (middle), (*M*, 4*aR*, 8*aS*)-**MeP[5]DA-1** (bottom) and the racemic mixture *rac*-**MeP[5]DA-1** (top).




Fig. S56. (a) UV-Vis Spectrum and (b) experimental ECD spectroscopy of *rac*-MeP[5]DA-1 recorded in CH₂Cl₂ (55 μM).




Fig. S57. Experimental and calculated ECD spectra of (*M*)-MeP[5]DA-1 (red) and (*P*)-MeP[5]DA-1 (blue) recorded in CH₂Cl₂ (55 μM). The initial structures were extracted from the single crystal data and optimised at DFT-D3 b3lyp/6-31+g(d,p)⁸ level with solvent set of dichloromethane (CH₂Cl₂). The calculated ECD spectra were also performed in CH₂Cl₂ at TD-DFT cam-b3lyp/6-311g(d,p) level with nstates of 30.




Fig. S58. (a) Variable temperature ECD spectra of (*P*)-MeP[5]DA-1 recorded in MeCN (20 μM). (b) ECD spectra of (*P*)-MeP[5]DA-1 recorded in CH₂Cl₂ (55 μM) and in MeCN (20 μM) at 298 K.




Fig. S59. HPLC chromatogram (gradient of chloroform/toluene, 20:80, $\lambda = 300$ nm) of **MeP[5]DA-2**.




Fig. S60. HPLC chromatogram (gradient of Chloroform/Toluene, 10:90, $\lambda = 300$ nm) of **EtP[5]DA**.




Fig. S61. HPLC chromatogram (gradient of Chloroform/*n*-hexane, 60:40, $\lambda = 300$ nm) of **EtP[6]DA**.




Fig. S62. Variable temperature NMR spectra of **MeP[5]DA-1** recorded in DMSO-*d*₆ from 298 K to 418 K.




Fig. S63. Variable temperature NMR spectra of **MeP[5]DA-1** recorded in CDCl₃ from 228 K to 298 K.

6. Reference

1. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howarda J. A. K.; Puschmann, H. *J. Appl. Cryst.* **2009**, *42*, 339–341.
2. Sheldrick, G. M. *Acta Cryst. Sect.* **2008**, *64*, 112–122.
3. Han, C.; Zhang, Z.; Yu, G.; Huang, F. *Chem. Commun.* **2012**, *48*, 9876–9878.
4. Kou, Y.; Cao, D.; Tao, H.; Wang, L.; Liang, J.; Chen, Z.; Meier, H. *J. Incl. Phenom. Macrocycl. Chem.* **2013**, *77*, 279–289.
5. Wu, X.; Chen, Y.; Hu, W.; Liu, Y.; Jia, X.; Li, J.; Jiang, B.; Wen, K. *Org. Biomol. Chem.* **2017**, *15*, 4897–4900.
6. Cao, J.; Shang, Y.; Qi, B.; Sun, X.; Zhang, L.; Liu, H.; Zhang, H.; Zhou, X. *RSC Adv.* **2015**, *5*, 9993–9996.
7. Avei, M. R.; Etezadi, S.; Captain, B.; Kaifer, A. E. *Commun. Chem.* **2020**, *3*, 117–131.
8. Gaussian 09, Revision D.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2013.